anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
An electrostatic process is used for coating a biological material with a uniform, continuous polymer layer by discharging a suspension of the biological material in a gelable coating polymer solution in a continuous stream through an orifice into an electrostatic field. The stream is attenuated to form droplets by maintaining an electrostatic voltage between the needle and the gelling solution which is sufficient to maintain an attraction of at least 1×10 -6  newtons on the stream of liquid leaving the needle, and the droplets are collected in a gelling solution. A preferred product is pancreatic islets having a continuous, smooth coating of high polymannuronate non-fibrogenic alginate having a thickness less than 200 μm such as about 20-200 μm. The alginate preferably contains less than 1 wt. % fucose, less than 0.5 wt. % sulfate and less than 0.01 wt. % phloroglucinol, is free of fibrinoogenic concentration of protein, and has a mannuronate to guluronate ratio of from 1.2 to 6. Preferably, the electrostatic field is formed by applying an electrostatic continuous DC voltage to each the needle and gelling solution so that the needle and solution have opposite charges.
The present invention relates to a quadrisected mask pack which increases the skin contact rate thereof and a method for producing the mask pack. The mask pack has become a type of functional cosmetic products which effectively remove body waste and recover physiological function of the skin. However, the mask pack has a demerit that some adhesion problems are generated. Research and development on a hydrogel for mask packs have recently been made actively in order to overcome the demerit. The hydrogel for mask packs is prepared by enabling hydrophilic hydrocolloids such as agarose, alginate, xanthan gum, guar gum, agar and others to form a three-dimensional matrix by physicochemical bond. A mask pack is produced by using as material a water-soluble hydrogel which is swollen using water as a solvent. It is general that the hydrogel is added to a synthetic resin, a nonwoven fabric, a net and others before using since the hydrogel alone is not capable of retaining appearance. However, there are many cases that the hydrogel is separated from the nonwoven fabric, and there is a possibility that a gel-phased hydrogel is capable of eluting chemical components of the synthetic resin if the synthetic resin and others are used. Therefore, it is required to examine the hydrogel in skin affinity and safety aspects. Further, a support that plays a role of holding a cosmetic solution is not hygienically good since the support is easily exposed to microorganisms such as molds, bacteria and others. Although an antiseptic should be added to prevent this problem, skin troubles may be caused by the antiseptic. In case of a formulation which induces consistent absorption of the cosmetic solution by soaking the support in the cosmetic solution, there are problems that skin adhesion is lowered, and the mask pack is detached from the face of a user since water is gradually evaporated as time passes after attaching the mask pack.
Participants received oral glecaprevir/pibrentasvir 300 mg/120 mg once daily (QD) for 12 or 16 weeks. Participants received treatment for 12 weeks with the exception of treatment-experienced, genotype 3-infected participants who received treatment for 16 weeks.
FIELD: chemical-pharmaceutical industry, pharmacy. SUBSTANCE: agent has paracetamol, acetylsalicylic acid, purine alkaloid and opium alkaloid as the main components. Caffeine base or caffeine sodium benzoate is used as purine alkaloid; codeine base or codeine phosphate is used as opium alkaloid; starch, microcrystalline cellulose and talc can be used as accessory substances taken in the definite ratio of components. Invention relates to also a method of drug preparing. Invention provides decrease of codeine dose being the claimed codeine dose provides to exclude drug from narcotic agents catalog that provides to obtain this drug without prescription and this medicinal form can be used for treatment of wide-spread inflammatory and catarrhal disease with the pain syndrome of different etiology. EFFECT: enhanced effectiveness of drug. 3 cl, 2 ex
Patients diagnosed with stage 3/ 4 cancer will be enrolled. After providing informed consent, patients will be asked to wear a FitBit Charge HR continuously for 8 weeks with the option to continue wearing the monitor for up to a year after end-of-study. Baseline assessments include a physical exam, medical history, and frailty assessment. The attending oncologist will rate the patient's performance status (ECOG PS) at baseline and 8-weeks follow-up. Patient-reported outcomes (self-reported physical function, fatigue, sleep, emotional distress) will be assessed weekly using NIH PROMIS from baseline up to 8 weeks from end-of-study. They will also be collected at 1 year follow-up. Wearable activity monitor data will be summarized each week for 8 weeks, and then again at 1 year follow-up. Physical activity data (number of steps, stairs climbed, active minutes, heart rate, and sleep duration) will be collected and analyzed at end-of-study (up to 1 year from end-of-study). Overall survival will also be assessed up to 1 year from end-of-study. Absolute change in physical activity levels will be correlated with change in performance status and occurrence of AEs and death to better understand the role of remote activity monitoring in cancer patients.
The aim of this study is to investigate potential changes in the microbiome of the oral cavity and/or gut in patients with hyperphosphatemia following Velphoro® intake for one month. The principal intention of this study is to assess consequences of Velphoro® medication beyond phosphate control. Adherence to the drug might be compromised by e.g. staining of teeth and biofilm after chewing the product more than recommended. Most likely this is a cosmetic problem only and easy to solve by optimizing oral hygiene. The increased level of iron may have an effect on the gut microbiome which could lead to mild diarrhoea. However, the present study will assess, whether the microbiome both oral and gut changes significantly due to some iron bio-availability, although this is expected to be low with sucroferric oxyhydroxide.

The ultimate goal is to improve patient adherence to the drug and to resolve potential safety concerns.
To evaluate the usefulness of the Tokyo Metropolitan Government's Eye Health Screening Program for 3-year-old children, which combines the Single-Picture Optotype Visual Acuity Chart (SPVAC) and Spot™ Vision Screener (SVS) tests. This was a retrospective, observational, matched study. Patients who underwent the eye health screening program and had abnormalities were classified into 3 groups according to the outcomes of the SPVAC (SPVAC-passed, SPVAC-P; SPVAC-failed, SPVAC-F) and SVS (SVS-passed, SVS-P; SVS-failed, SVS-F) tests as follows: SPVAC-P/SVS-F, SPVAC-F/SVS-P, and SPVAC-F/SVS-F. We evaluated the age at examination, SPVAC and SVS test success rates, and SVS refractive power. Additionally, the rates of refractive error, amblyopia, and strabismus were compared among the 3 groups. The SPVAC-P/SVS-F, SPVAC-F/SVS-P, and SPVAC-F/SVS-F groups comprised 158, 28, and 74 eyes, respectively. The mean age was 37.4 months. The success rates of the SPVAC and SVS tests were 69.8% and 96.2%, respectively. The mean SVS hyperopia value in the SPVAC-F/SVS-F group (2.71 ± 1.50 D) was significantly higher than that of the SPVAC-P/SVS-F group. The mean SVS astigmatism and myopia values were -2.21 diopter (D) ± 1.09 D and -3.40 ± 1.82 D, respectively; they did not differ significantly from that of the SPVAC-P/SVS-F group. Significant differences were observed in the refractive error, amblyopia, and strabismus rates among the 3 groups. Regarding disease determination, no significant difference was observed among participants who passed and failed the SPVAC test, regardless of the outcome of the other test. However, a significant difference was observed between those passing and failing the SVS tests. The SPVAC method used to screen 3-year-old children should be modified to commence at 42 months of age or be replaced with a single Landolt C test. The SVS test is useful for screening younger patients. Furthermore, the SVS test showed that the degree of hyperopia was higher in patients who did not pass the SPVAC test.
BACKGROUND: Several neurological manifestations shortly after a receipt of coronavirus infectious disease 2019 (COVID-19) vaccine have been described in the recent case reports. Among those, we sought to evaluate the risk of encephalitis and meningitis after COVID-19 vaccination in the entire South Korean population.
METHODS: We conducted self-controlled case series (SCCS) analysis using the COVID-19 immunization record data from the Korea Disease Control Agency between February 2021 and March 2022, linked with the National Health Insurance Database between January 2021 and October 2022. We retrieved all medical claims of adults aged 18 years or older who received at least one dose of COVID-19 vaccines (BNT162b2, mRNA-1273, ChAdOx1-S, or Ad26.COV2.S), and included only those who had a diagnosis record for encephalitis or meningitis within the 240-day post-vaccination period. With day 0 defined as the date of vaccination, risk window was defined as days 1-28 and the control window as the remainder period excluding the risk windows within the 240-day period. We used conditional Poisson regression to estimate the incidence rate ratios (IRR) with 95% confidence intervals (CI), stratified by dose and vaccine type.
RESULTS: From 129,956,027 COVID-19 vaccine doses administered to 44,564,345 individuals, there were 251 and 398 cases of encephalitis and meningitis during the risk window, corresponding to 1.9 and 3.1 cases per 1 million doses, respectively. Overall, there was an increased risk of encephalitis in the first 28 days of COVID-19 vaccination (IRR 1.26; 95% CI 1.08-1.47), which was only significant after a receipt of ChAdOx1-S (1.49; 1.03-2.15). For meningitis, no increased risk was observed after any dose of COVID-19 vaccine (IRR 1.03; 95% CI 0.91-1.16).
CONCLUSIONS: Our findings suggest an overall increased risk of encephalitis after COVID-19 vaccination. However, the absolute risk was small and should not impede COVID-19 vaccine confidence. No significant association was found between the risk of meningitis and COVID-19 vaccination.
Do you the invention provides a kind of Heme oxygenase 1 (heme of the PRRS of inhibition virus infected cell? oxygenase1, and the derivant Copp (Cobalt of HO-1 HO-1)? Protoporphyrin, CoPP) and protoferriheme (hemin) as blocking agent, suppress the method for PRRSV infection cell. Pig HO-1 gene is remarkable up-regulated expression after highly pathogenic PRRSV infects, and after classical PRRSV infects, significantly lowers expression. The HO-1 gene of the permissive cell African green monkey kidney cell line of PRRSV also remarkable up-regulated expression after highly pathogenic PRRSV infects, and also significantly lower and express after classical PRRSV infects. Utilize the HO-1 of CoPP and hemin induction Marc-145 and porcine alveolar macrophage (PAM) to express. Result shows both significantly to have induced the expression of HO-1, has suppressed PRRSV and has infected Marc-145 and PAM cell.
The study requires a total of three visits to Battelle's laboratory: one screening visit and two experimental visits. The screening visit will determine eligibility into the study. If eligible, participants will smoke a tobacco cigarette through the Clinical Research Support System (CReSS) puff topography device. Enrolled participants will attend two separate 5-hour experimental visits. Participants will be randomly assigned the order of THC potency (active or placebo), with the assignment blocked by sex. When participants arrive at the laboratory for each visit, they will provide biologic samples to verify compliance with pre-study instructions and then will be taken to a specially ventilated smoking chamber. They will be connected to a continuously-monitoring heart rate and blood pressure machine so that their vital signs can be observed throughout the smoking session. A research assistant will give a marijuana cigarette to the participant. A research assistant will light the cigarette and then exit the room. Participants will follow tape-recorded instructions for smoking the marijuana cigarette through the CReSS device. Upon completion of smoking the marijuana cigarette, participants will complete the Tobacco Craving Questionnaire via paper and pencil and will then be allowed to smoke one of his own tobacco cigarettes through the CReSS puff topography device. Participants will be allowed to smoke as many tobacco cigarettes as they would like for the next 3 hours. Participants will then be given lunch and sent home via taxicab. All participants will receive both potencies (i.e., active and placebo) of marijuana. The active potency of marijuana will be 5.6% THC.
ATRIPLA is a fixed-dose combination tablet containing efavirenz, emtricitabine, and tenofovir disoproxil fumarate (tenofovir DF). SUSTIVA is the brand name for efavirenz, a non-nucleoside reverse transcriptase inhibitor. EMTRIVA is the brand name for emtricitabine, a synthetic nucleoside analog of cytidine. VIREAD is the brand name for tenofovir DF, which is converted in vivo to tenofovir, an acyclic nucleoside phosphonate (nucleotide) analog of adenosine 5'-monophosphate. VIREAD and EMTRIVA are the components of TRUVADA.

ATRIPLA tablets are for oral administration. Each tablet contains 600 mg of efavirenz, 200 mg of emtricitabine, and 300 mg of tenofovir DF (which is equivalent to 245 mg of tenofovir disoproxil) as active ingredients. The tablets include the following inactive ingredients: croscarmellose sodium, hydroxypropyl cellulose, magnesium stearate, microcrystalline cellulose, and sodium lauryl sulfate. The tablets are film-coated with a coating material containing black iron oxide, polyethylene glycol, polyvinyl alcohol, red iron oxide, talc, and titanium dioxide.
Risks from Concomitant Use with Opioids

Concomitant use of phenobarbital products, including SEZABY, and opioids may result in profound sedation, respiratory depression, coma, and death. Reserve concomitant prescribing of these drugs for patients for whom alternative treatment options are inadequate. If a decision is made for concomitant use of these drugs, limit dosages and durations to the minimum required, and follow patients for signs and symptoms of respiratory depression and sedation [see Warnings and Precautions (5.1) and Drug Interactions (7.3)].

Dependence and Withdrawal Reactions After Use of SEZABY for a Longer Duration than Recommended

The continued use of phenobarbital may lead to clinically significant physical dependence. The risks of dependence and withdrawal increase with longer treatment duration and higher daily dose. Although SEZABY is indicated only for short-term use [see Indications and Usage (1) and Dosage and Administration (2)], if used for a longer duration than recommended, abrupt discontinuation or rapid dosage reduction of SEZABY may precipitate acute withdrawal reactions, which can be life-threatening. For patients receiving SEZABY for longer duration than recommended, to reduce the risk of withdrawal reactions, use a gradual taper to discontinue SEZABY [see Warnings and Precautions (5.2)].

Abuse, Misuse, and Addiction with Unapproved Use in Adolescents and Adults

SEZABY is not approved for use in adolescents or adults. The unapproved use of SEZABY, in adolescents and adults exposes them to risks of abuse, misuse, and addiction, which can lead to overdose or death. Abuse and misuse of phenobarbital commonly involve concomitant use of other drugs, alcohol, and/or illicit substances, which is associated with an increased frequency of serious adverse outcomes [see Warnings and Precaution (5.3)].
PURPOSE: A skin massage tool is provided to effectively absorb ingredients into skin using Opuntia fruits containing a large amount of vitamin C as a main ingredient. CONSTITUTION: A skin massage tool comprises: a massage composition sheet member (31) containing a massage sheet which is made of a non-woven fabric in a glove or sock shape and a skin massage composition which is impregnated into the massage sheet; and an airtight member (32) which is made of a plastic material in a glove or sock shape and tightly surrounds the sheet member. The skin massage composition contains a natural plant ingredient, polyol, oil ingredients, a surfactant, phospholipid, and purified water. The natural plant ingredient is an Opuntia fruit extract. The polyol is butylene glycol and glycerin. The surfactant is polysorbate. The oil ingredient and the phospholipid are acrylate, hydroxyl ethyl cellulose, mineral oil, betaine, phenoxy ethanol, sorbitan sesquioleate, methyl parabene, triethanol amine, and propylparaben.
In this single-center, vehicle gel-controlled, evaluator and subject blinded study, approximately 30 otherwise healthy adult subjects with elevated P. acnes counts will be randomized 2:1 to NVN1000 4% Gel or Vehicle Gel. The subjects will apply the test material twice daily to their face after washing. Subjects will be seen daily at the skin study center during the week and will apply their evening and weekend dose at home. Cutaneous tolerability will be assessed by the Investigator at Baseline, Week 1, and Week 2. Safety assessments include collection of adverse events, laboratory results, and clinically significant changes in physical examination. P. acnes counts will be obtained at Baseline, Week 1 and Week 2.
Methods, systems, and apparatus, including computer programs encoded on a computer storage medium, for obtaining data for a set of patients that each have a certain condition. A first and second sequence of data is determined based on the obtained data. A scoring model is generated by processing the first and second sequence of data to train a neural network. The scoring model determines a confidence that an individual has the particular healthcare condition. Patient scoring data is provided to the scoring model to determine the confidence that the individual has the healthcare condition. A confidence score is received as an output of the scoring model in response to providing the patient scoring data. The confidence score represents a determined confidence that the individual has the healthcare condition. An indication that represents the confidence that the individual has the healthcare condition is provided based on the received confidence score.
PURPOSE: A radio sensitizer composition for radiation treating cancer cells bromo domain of brg-1 originated or a fraction thereof or a nucleic acid coding the same are provided to increase radiation sensitivity, thereby increasing apoptosis. CONSTITUTION: A radio sensitizer composition includes a fraction having bonding activities to BRG-1 derivative bromo domain or acetylation histone as an active ingredient. The radio sensitizer composition includes separated nucleic acid or a vector having the nucleic acid which codes the fraction as the active ingredient. The cancer cell is colon cancer, lung cancer or hepatoma cell. The fraction of BRG-1 derivative bromo domain has the activity of uniting with acetylated K14 of H3. The bromo domain or the fraction of the BRG-1 derivative additionally includes cell internalization sequence. The bromo domain or the fraction of the BRG-1 derivative additionally includes a tumor unique targeting sequence.
A series of rat reproduction studies was performed with diazepam in oral doses of 1, 10, 80 and 100 mg/kg. At 100 mg/kg there was a decrease in the number of pregnancies and surviving offspring in these rats. Neonatal survival of rats at doses lower than 100 mg/kg was within normal limits. Several neonates in these rat reproduction studies showed skeletal or other defects. Further studies in rats at doses up to and including 80 mg/kg/day did not reveal teratological effects on the offspring.

In humans, measurable blood levels of diazepam were obtained in maternal and cord blood, indicating placental transfer of the drug.
The invention belongs to the technical field of traditional Chinese medicines, and particularly relates to a traditional Chinese medicine composition for treating sexual precocity of children, and a preparation method and application thereof. The traditional Chinese medicine composition is prepared from the following raw materials in parts by weight: 3-12 parts of pinellia ternate, 5-15 parts of poria cocos, 3-15 parts of radix scrophulariae, 6-15 parts of rhizoma anemarrhenae, 3-10 parts of gentian, 6-24 parts of tortoise shell, 3-15 parts of spina gleditsiae and 6-30 parts of oyster. The invention combines the modern traditional Chinese medicine pharmacological research, mainly resolves phlegm and clears heat, and simultaneously softens hardness and dissipates stagnation as the treatment principle, treats both principal and secondary aspects of diseases, regulates the internal and external functions, has high efficiency and has no obvious toxic and side effects. The prescription is flexible to use and low in cost. The traditional Chinese medicine composition is prepared into granules, and has the advantages of obvious curative effect, short treatment course, convenience in use and small irritation. The preparation method is simple, the preparation cost is low, and the preparation method has great economic value and clinical application value.
The invention discloses an oral composition taking oseltamivir phosphate as a main drug and a preparation method thereof, wherein oseltamivir phosphate is mixed with a waxy matrix to obtain drug-containing particles, and a hot-melt extrusion process is preferred; and then mixing with other auxiliary materials to obtain oral solid compositions such as capsules, granules, dry suspensions and the like. The waxy base is selected from long chain fatty acids having 14 to 20 carbon atoms, preferably saturated fatty acids, more preferably stearic acid. Has the following advantages: (1) The fluidity of the particles is good, and the prepared preparation has uniform content. (2) The preparation has no unpleasant smell, no bitter taste in mouth, and good patient compliance, and is especially suitable for infants and children patients. And (3) the production process is simple and easy to operate, and the cost is low. (4) stable quality. (5) The stability of the preparation is obviously improved, and the generation speed of degradation products is obviously reduced.